Loading...
XNAS
ALT
Market cap339mUSD
Jul 16, Last price  
4.18USD
1D
0.00%
1Q
-8.13%
Jan 2017
-96.37%
IPO
-40.20%
Name

Altimmune Inc

Chart & Performance

D1W1MN
XNAS:ALT chart
P/E
—
P/S
16,951.36
EPS
—
Div Yield, %
—
Shrs. gr., 5y
40.16%
Rev. gr., 5y
-67.83%
Revenues
20k
-95.31%
586,0741,847,71214,643,61532,911,32827,549,97820,993,60524,266,27425,175,88717,912,60710,190,20510,640,6605,230,19641,50310,331,1685,801,4018,185,0274,410,356-68,000426,00020,000
Net income
-95m
L+7.48%
277,2951,016,334-13,587,303-36,415,113-32,279,760-34,849,277-3,797,573-4,920,115-11,718,353-9,955,395-3,440,705193,854,173-46,425,390-39,171,152-20,520,131-49,044,477-96,171,311-84,713,000-88,447,000-95,059,000
CFO
-80m
L+5.33%
554,3341,528,426-13,636,712-13,198,574-28,145,650-14,864,577-7,808,553-2,322,906-7,168,204-8,474,042-3,215,981201,508,238-20,214,079-9,388,908-9,601,997-34,436,636-78,237,941-62,586,000-75,810,000-79,848,000
Dividend
Jan 20, 2017291.0033 USD/sh
Earnings
Aug 06, 2025

Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
URL
https://altimmune.com/
IPO date
Oct 06, 2005
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
20
-95.31%
426
-726.47%
(68)
-101.54%
Cost of revenue
103,192
84,413
87,740
Unusual Expense (Income)
NOPBT
(103,172)
(83,987)
(87,808)
NOPBT Margin
129,129.41%
Operating Taxes
(197)
Tax Rate
NOPAT
(103,172)
(83,987)
(87,611)
Net income
(95,059)
7.48%
(88,447)
4.41%
(84,713)
-11.91%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,994
87,031
56,265
BB yield
-1.95%
-14.53%
-7.29%
Debt
Debt current
279
496
452
Long-term debt
3,083
846
1,796
Deferred revenue
Other long-term liabilities
3,928
4,223
3,909
Net debt
(128,529)
(196,473)
(182,632)
Cash flow
Cash from operating activities
(79,848)
(75,810)
(62,586)
CAPEX
(47)
(126)
Cash from investing activities
(28,386)
13,732
(73,399)
Cash from financing activities
10,044
86,105
56,781
FCF
(102,407)
(84,084)
(87,244)
Balance
Cash
131,891
197,815
184,880
Long term investments
Excess cash
131,890
197,794
184,883
Stockholders' equity
(566,356)
(471,328)
(383,106)
Invested Capital
695,473
670,321
572,263
ROIC
ROCE
EV
Common stock shares outstanding
71,003
53,247
46,926
Price
7.21
-35.91%
11.25
-31.61%
16.45
79.59%
Market cap
511,935
-14.54%
599,028
-22.40%
771,938
104.13%
EV
383,406
402,555
589,306
EBITDA
(102,934)
(83,510)
(88,013)
EV/EBITDA
Interest
9
35
8
Interest/NOPBT